ERBB2 and breast cancer: This is in accordance with the results of the NSABP-B47 trial that failed to show improved disease-free survival if trastuzumab is added to chemotherapy in patients with HER2-low (IHC 1+ or 2+ staining intensity) breast cancer [13].